
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease
Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT.
The RMAT designation is
At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union
No adverse events
BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its
Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors
Oct 1, 2024
Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares
Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes
BiocSol secures €5.2M seed funding to transform sustainable crop protection with next generation microbial-based solutions, targeting total €10M in funding by year-end
ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development
• Financing co-led by EQT Life Sciences and MRL Ventures Fund (MRLV